Priliximab

Priliximab
Monoclonal antibody
Type Whole antibody
Source Chimeric (mouse/human)
Target CD4
Identifiers
CAS Number 147191-91-1 N
ATC code None
ChemSpider none
 NYesY (what is this?)  (verify)

Priliximab (cMT 412) is a human-mouse chimeric anti-CD4 monoclonal antibody. It has been tested on patients with Crohn's disease[1] and multiple sclerosis[2][3] but has not yet received U.S. Food and Drug Administration licensing. The patent belongs to the biotechnology company Centocor.

References

  1. Stronkhorst A, Radema S, Yong S, Bijl H, ten Berge I, Tytgat G, van Deventer S (1997). "CD4 antibody treatment in patients with active Crohn's disease: a phase 1 dose finding study". Gut 40 (3): 320–7. doi:10.1136/gut.40.3.320. PMC 1027080. PMID 9135519.
  2. Llewellyn-Smith N, Lai M, Miller D, Rudge P, Thompson A, Cuzner M (1997). "Effects of anti-CD4 antibody treatment on lymphocyte subsets and stimulated tumor necrosis factor alpha production: a study of 29 multiple sclerosis patients entered into a clinical trial of cM-T412". Neurology 48 (4): 810–6. doi:10.1212/wnl.48.4.810. PMID 9109860.
  3. van Oosten B, Lai M, Hodgkinson S, Barkhof F, Miller D, Moseley I, Thompson A, Rudge P, McDougall A, McLeod J, Adèr H.J., Polman C (1997). "Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial". Neurology 49 (2): 351–7. doi:10.1212/wnl.49.2.351. PMID 9270561.


This article is issued from Wikipedia - version of the Thursday, November 19, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.